基本信息
浏览量:13
职业迁徙
个人简介
Since 1995 his laboratory in Bristol has focused on the mechanism of antigen-specific immunotherapy. His work provided the essential rules governing the design of therapeutic peptides and led to the establishment of a University of Bristol spinout company, Apitope NV. The company has designed peptides for treatment of various autoimmune diseases and has successfully completed phase 2 trials in relapsing multiple sclerosis. David’s research laboratory is currently defining the differentiation pathway of antigen induced Treg cells and the mechanism by which these cells suppress disease. The aim of this approach is to improve the efficacy of peptide therapy for treating allergic and autoimmune diseases in man
研究兴趣
论文共 76 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CURRENT OPINION IN IMMUNOLOGY (2021): 75-81
FRONTIERS IN IMMUNOLOGY (2020): 1586-1586
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn